The recent clinical trial in lymphoma using tumor antigenloaded DCs (Hsu et al, Nature Med 1996; 2: 52) demonstrates the efficiency of the use of professional antigen presenting cells (APCs) for taking up, processing and presenting tumor protein in a vaccine strategy in cancer. However, the production of large quantities of clinical grade APCs remains to be resolved. Here, we describe that both dendritic cells (DCs) and macrophages (MØs) can be efficiently differentiated in large numbers from lymphoma patients in spite of their disease and previous therapy. These cells were produced using the VAC and MAK cell processors according to standard operating procedures. DCs and MØs were differentiated from circulating monocytes in gas permeable hydrophobic bags, with 2% autologous serum and in the presence of GM-CSF and IL-13 or GM-CSF alone, respectively. DCs and MØs were then purified by counter flow centrifugation. Phenotypic, morphological and functional analysis showed that cells differentiated from patients with lymphoma present quite similar features to DCs and MØs produced from monocytes of healthy donors. Moreover, we show that MØs, when combined with CD20 antibody (Rituximab), can efficiently engulf tumor cells and propose that a such combination could be used for initiating a clinical trial in lymphoma. Thus, the possibility of producing functional DC and MØs in large amounts in conditions compatible with therapeutic application will allow the development of new immune strategies to eradicate lymphoma.
Introduction
B cell-derived non-Hodgkin's lymphomas (NHL) constitute an heterogeneous group of lymphoid malignancies which most often remain incurable with conventional treatments. 1 One therapeutic alternative is the modulation of the immune system to eliminate neoplastic cells. In vivo, the immune system has failed to spontaneously develop effective immunity against tumor cells. However, antitumor reactive T lymphocytes can be found among tumor infiltrating lymphocytes, 2, 3 and autologous antitumor CTL can be efficiently expanded in vitro. 4, 5 Moreover, we have shown that, even if they are resist- ant to the CD95-mediated apoptosis pathway, 6 malignant B cells can be efficiently destroyed by CD8
+ CTL via the perforin/granzyme exocytosis pathway. Recent clinical trials using tumor-specific idiotype as a vaccine have shown that antitumor T cells can also be generated in vivo. Indeed, the injection of immunizing protein with an adjuvant, 7 or with dendritic cells (DCs) 8 was associated in both cases with the development of antitumor reactive T lymphocytes. This approach is, however, limited by the difficulty in producing the autologous tumor idiotype for each patient. An alternative approach would be to use the tumor cells as a direct source of antigen and appropriate APC to vaccinate patients. For example, such an approach with DCs pulsed with tumor cell lysates has been used for the treatment of melanoma 9 and renal cell cancer. 10 Two types of APC could be used for the development of adoptive immunotherapy of cancer: macrophages (MØs) and DCs. Indeed, both are able to process and present antigens to helper and cytotoxic T lymphocytes. [11] [12] [13] [14] [15] [16] [17] The adoptive transfer of MØs was first proposed based on their tumoricidal potential, with the hope that they might also induce a T cell response. The development of technology allowing the scaling up of the generation of MØs in vitro from monocytes allowed clinical trials using MØs in cancer patients and the feasibility and safety of MØs infusions to be established (for review see Refs 18 and 19) . The clinical evidence of a direct antitumor effect of MØs adoptive immunotherapy is, however, rather limited, with rare observations of reduction in malignant ascites, 20 disease stabilization or partial response. 21, 22 One explanation for this failure may be that the MØs were not targeted to the malignant cells. In order to improve the antitumor effect of MØs, antitumor monoclonal antibodies or bispecific antibodies could be used in combination with MØs. 23, 24 Some ongoing clinical trials aim to use the APC functions of MØs 25, 26 by loading them with tumor antigens before injection into patients (Toujas L, personal communication) .
Dendritic cells are defined as professional antigenpresenting cells, with a strong capacity for initiating primary T lymphocyte responses. 27 DC-based vaccines are under active investigation and are entering clinical evaluation. Ag-pulsed DCs have been shown to induce clinical responses associated with the development of antitumor T cell responses, even for patients with advanced cancer, in B cell lymphoma, 28 mela-noma, 9 renal cell cancer 10 or prostate cancer. 29 In these studies, different types of antigen were chosen: known specific tumor-associated antigenic peptide or protein and whole tumor cell lysates. Although clinical trials with DCs seemed more efficient than trials with MØs, the choice of the immunizing APC remains debatable. Indeed, the use of DCs or MØs may depend on the kind of cancer, the tumor location and its accessibility, the existence and availability of tumor antigen(s), and the need to develop a naive or memory T cell response.
In B cell lymphomas, the tumor-associated antigen used for vaccination was the tumor idiotype. 28 Even though clinical studies have shown this treatment to be effective, the use of the idiotype, which is unique for each patient, is not practical for every patient and the development of new approaches is justified. With the aim of using whole tumor cell preparations as a source of tumor antigen in combination with professional APC, we analyzed the capacity of peripheral blood mononuclear cells to differentiate in vitro into MØs and DCs in conditions allowing their use in clinical trials. This study was performed with cells from healthy volunteers and patients with non-Hodgkin's B cell-derived lymphomas. We show that both DCs and MØs can be efficiently differentiated in large numbers in vitro from lymphoma patients in spite of their disease and previous therapy. These two populations of APC were compared for their potential to activate T lymphocyte responses and their ability to capture antigens by phagocytosis.
Materials and methods

Antibodies and medium
The following antibodies were used, conjugated with fluorescein isothiocyanate or phycoerythrin: BL6 (CD1a), L161 (CD1c), UCHT-1 (CD3), 13B8.2 (CD4), B9.11 (CD8), BEAR-1 (CD11b), BU15 (CD11c), RMO52 (CD14), 3G8 (CD16), J4.119 (CD19), 2E1 (CD32), J3D3 (CD35), mAb89 (CD40), N901 (CD56), 22 (CD64), MAB104 (CD80), HB-15a (CD83), B9.12.1 (HLA-ABC), B8.12.2 (HLA-DR) (Immunotech, Marseille, France); 679.1Mc7, U7.27 and MOPC-195: irrelevant control (Immunotech); monoclonal FITC-conjugated goat antimouse immunoglobulins (FITC-GAM) (DAKO, Glostrup, Denmark); 2331(FUN-1) (CD86) (Pharmingen, San Diego, CA, USA). The following unconjugated mAb were used: BL6 (CD1a), L161 (CD1c), RMO52 (CD14), B8.12.2 (HLA DR) (Immunotech) and W6/32 directed against HLA-ABC (Serotech, Oxford, UK). For immunofluorescence studies, experiments were performed in Hank's balanced salt solution (HBSS) supplemented with 2% new-born calf serum. Cell cultures were performed at 37°C in 5% CO 2 humidified air.
Generation of dendritic cells and macrophages
Mononuclear cells:
Six normal volunteers (N1 to N6, three men and three women, mean age = 41 years) and two patients with a malignant non-Hodgkin's lymphoma (L1 and L2), who gave informed consent, were included in this study. L1 and L2 were both men (40 and 49 years old) with mucosa-associated lymphoid tissue and follicular lymphoma, respectively. Patients were in clinical complete remission before apheresis, and 7 and 11 months, respectively, from their last treatment.
Peripheral 
Culture and purification of dendritic cells and macrophages:
In seven cases, two cultures were performed in parallel to generate either DCs or MØs. In one case (N1), mononuclear cells were differentiated into DCs only. The cultures were performed using the same process as MAK cell processor and VAC cell processor developed by ImmunoDesigned Molecules (Paris, France) for production of clinical grade MØs and DCs, respectively, using standard operating procedures. [30] [31] [32] These cell processors contain all culture, collection and purification bags as well as all connections and tubings made of biocompatible plastic. The cell processors also include the specific culture medium, washing and elutriation solutions, and antibodies for phenotyping of the final cell product. Dedicated software explains in detail all the steps in the preparation and ensures clear tracking from cytapheresis all the way to reinjection in the patient. All equipment and media are endotoxin-free and are submitted to all the quality controls required for clinical grade cells. Briefly, DCs and MØs were differentiated from 500 × 10 6 mononuclear cells cultured in gas-permeable hydrophobic bags (Stedim, Aubagne, France) in 100 ml of medium supplemented with 2% autologous plasma recalcified with CaCl 2 . All cell cultures were performed at 37°C in 5% CO 2 humidified air. For differentiation into MØs, the culture medium used was Iscove's modified Dulbecco's medium (IMDM) according to Immuno-Designed Molecules specifications enriched with GM-CSF (500 U/ml Sandoz, Reuil-Malmaison, France). Cells were recovered on day 7, analyzed and cryopreserved. Dendritic cells were generated in RPMI 1640 (Life Technologies, Cergy Pontoise, France) supplemented with 1 mM sodium pyruvate, 2 mM L-glutamine, 100 U/ml penicillin, 100 g/ml streptomycin, non-essential amino acids (referred to as complete medium) and with 500 U/ml GM-CSF (Sandoz) and 50 ng/ml IL-13 (Sanofi, New York, USA). Fresh IL-13 was added on day 3. Cells were recovered on day 6, analyzed and cryopreserved. In two cases (N6 and L2), the differentiated DCs and MØs were separated from lymphocytes by elutriation according to their size in a counter current centrifuge (Beckman, Fullerton, CA, USA). In two other cases (N5 and L1), the differentiated DCs and MØs were separated from lymphocytes by immunomagnetic negative selection, with mAb CD3, CD20 and CD56 (Immunotech) and Dynabeads (M450, Dynal, Oslo, Norway). Day 6 DCs and day 7 MØs purified contained less than 5% lymphocytes. Morphologic and phenotypic analysis were performed on fresh cells. Further functional analysis were performed with cryopreserved cells.
Immunophenotype analysis Flow cytometry:
Immunophenotyping was performed by flow cytometry on a FACScan (Becton Dickinson, Mountain View, CA, USA). For single-or two-color direct or indirect immunofluorescence analysis, cells were incubated for 20 min at 4°C with specific antibodies and then washed twice. For indirect labeling, cells were further incubated with FITC-GAM and washed twice. Negative controls were isotypematched irrelevant immunoglobulins. Monocytes, DCs and MØs were gated during analysis according to their characteristic FSC/SSC profiles.
Immunocytochemistry:
Cytospins of cell suspensions were dehydrated, fixed with acetone (−20°C, 10 min) and cryopreserved. After thawing and rehydration, they were stained with an avidin-biotin-immunoperoxidase procedure (Sigma Aldrich, St Quentin Fallavier, France). According to the manufacturer's instructions, the incubation with primary antibodies (1 h) was followed by incubation with biotinylated goat antimouse Ig (30 min) and extravidin peroxidase (30 min). The reaction was revealed with diaminobenzidine and counterstaining with Mayer's hematoxylin (5 min) was performed.
Mixed lymphocyte reaction (MLR)
Responding T lymphocytes were normal PBMC obtained from two healthy adult male volunteers by density gradient centrifugation (MSL, Eurobio, Les Ulis, France). CD2
+ T and NK cells were isolated using a standard rosetting technique. Of these cells, less than 3% were CD19 + or CD14 + . The HLA class II phenotype of responder CD2
+ cells was mismatched both for DR and DQ with stimulator cells. The purified APC from healthy volunteer donors N5 and N6 and lymphoma patients L1 and L2 were stimulator cells.
Unidirectional MLR were conducted in quadruplicate in 0. 
Presentation of soluble antigens
The ability of generated APC to prime naive or memory autologous T lymphocytes was assessed by their ability to present soluble antigens, keyhole limpet hemocyanin (KLH) and purified protein derivative (PPD) antigens, and induce cell proliferation. Purified APC from healthy volunteer donors N5, N6 and lymphoma patients L1 and L2 were included. Responding lymphocytes were day 0 CD2
+ autologous lymphocytes purified from PBMC using a standard rosetting technique. Cultures were performed in 96-well round-bottom plates. Each well received 50 × 10 3 responding CD2 + cells and 5 × 10 3 APC (CD2 + lymphocytes/APC ratio = 10/1). Cultures were performed in complete medium supplemented with 10% HAS. KLH (Sigma) was added at 1, 10, 50 and 100 g/ml and PPD (Pasteur Mérieux, Lyon, France) was added at 2500 U/ml. After a 5-day culture, 1 Ci 3 H thymidine was added to each well and harvested 18 h later. Results are expressed as fold increase index (see above), with all control wells below 600 c.p.m.
Leukemia
Phagocytosis of bacteria
In six cases (N2 to N5, L1 and L2), the ability of DCs, MØs and monocytes were compared for their ability to engulf opsonized bacteria using FITC-labeled opsonized E. coli (Phagotest; Orpegen Pharma, Heidelberg, Germany). 5 × 10 5 cells were incubated with 20 × 10 6 bacteria (2 h, 37°C or 4°C for control), in complete medium supplemented with 50% human A serum. Quenching solution (Phagotest: Orpegen Pharma) was added to quench the fluorescence associated with non-internalized bacteria. Cells were then washed and analyzed by flow cytometry.
Phagocytosis of tumor B cells
In two cases (N6 and L2) the ability of DCs and MØs to phagocytose NHL malignant B cells was evaluated. Malignant B cells from three patients with follicular NHL were purified as described 33 and opsonized with a chimeric CD20 antibody (Rituximab; Roche, Reinach, Switzerland) at 1 g/ml for 1 h at 4°C. B cells were thus mixed in a 1/1 ratio with APC in polypropylene tubes in complete medium in 2% human albumin (LFB). Tubes were then incubated for 90 min at 37°C to allow phagocytosis. Cytospins were then done, and slides were dehydrated and stained with May-Grü nwald Giemsa. They were then examined microscopically for ingestion of malignant B cells by two experimenters and the percentage of phagocytic APC was determined by counting at least 200 cells.
Functionality of cocultured T lymphocytes
In six cases (N1 to N5 and L1), the functionality of T cells cocultured with APC was assessed by evaluation of their ability to respond to mitogenic stimuli. Total cells obtained at day 6 and day 7 were used and PBMC were used as control. 10 5 cells were added to each well in 96-well flat-bottom plates. Cultures were performed in complete medium supplemented with 10% HAS. Phytohemaglutinin A (PHA, Murex Diagnostic, Chatenay-Malabry, France), concanavalin A (ConA, Sigma Aldrich), OKT3 (CILAG) or pokweed mitogen (PWM, Sigma Aldrich) were added at 2 g/ml, 20 g/ml, 0.1 g/ml and 1 g/ml, respectively. After a 3-day culture with PHA, ConA and OKT3 or a 6-day incubation with PWM, 1 Ci 3 H thymidine was added to each well and harvested 8 h later. Results are expressed as fold increase index (see above).
In four cases (N1, N4, N5 and L1), the priming of T cells cocultured with DCs was assessed by measuring the response to KLH antigen. 10 5 day 0 and day 6 unseparated cells were added to each well in 96-well round-bottom plates. Cultures were performed with KLH as described above.
Results
Large numbers of dendritic cells and macrophages can be recovered after culture
Cultures for differentiation into MØs and DCs were performed in bags with peripheral blood mononuclear cells without any prior purification of monocytes and in the presence of autologous serum. Procedures complied with guidelines allowing the recovered cells to be used for therapeutic purposes. The Comparative analysis of the phenotype of DCs and Mлs. Cytospins of APC derived from healthy donor monocytes after 6 days with GM-CSF plus IL-13 (DCs) or after 7 days with GM-CSF (Mлs) were stained with the indicated mAb, revealed with diaminobenzidine and counterstained with Mayer's hematoxylin. Data are representative of eight cultures performed with both healthy donors and lymphoma patients. Original magnification ×40.
number of DCs and MØs recovered at the end of the culture was dependent on the percentage of monocytes among the day 0 mononuclear cells used (from 10 to 43%). Based on morphological analysis, it would appear that all monocytes differentiated during the culture. From 500 × 10 6 mononuclear cells a mean of 180 × 10 6 MØs and 100 × 10 6 DCs were recovered. Mean viability of total recovered cells was 70%. In some cases, at the end of the culture, cells were purified by elutriation and the yield of cell recovery was 60% and 90% for DCs and MØs, respectively. Contaminating lymphocytes represented less than 3% of the recovered purified APC.
Phenotype of DCs and MØs generated from mononuclear cells from healthy donors and lymphoma patients
For FACs analysis, monocytes, DCs and MØs were gated according to their characteristic FSC/SSC profile. The gated cells were negative for CD3, CD19 and CD56 molecules (data not shown).
After a 6-day culture with GM-CSF and IL-13, monocytes from healthy donors acquired phenotypic characteristics of DCs (Figure 1 ), whereas after 7 days with GM-CSF, they acquired the characteristics of MØs. Like the day 0 monocytes, the majority of MØs expressed CD14 (Table 1 ) and the Fc␥R CD64, which were lost by DCs. On the other hand, the characteristic DCs-associated markers, CD1c and CD1a, were acquired by 60% and 23% of the DCs, respectively, but not by the MØs. CD83 expression was very low on DCs, and absent in MØs (Figure 1 ). Regarding the expression of the molecules associated with APC functions, the majority of monocytes, DCs and MØs expressed HLA class I and II molecules, and CD40, but based on the intensity of labeling, the expression of these three molecules was higher on DCs compared to MØs and monocytes (data not shown). CD80 and CD86 were expressed by 43% and 53% of the MØs, compared to 59% and 98% on DCs, whereas CD80 was not expressed by monocytes. Fc receptors expressed by monocytes were modulated during differentiation: the Fc␥R CD32 was expressed by most MØs, but by only half of the DCs, and the CD16 molecule was weakly expressed by DCs compared to MØs. The receptors for complement CD11b, CD11c and CD35 expressed by monocytes were conserved in DCs and MØs.
Two cultures were performed with mononuclear cells from two lymphoma patients (Table 1) . Cells obtained after 6 days of culture with GM-CSF and IL-13 mostly expressed CD1c, CD80 and CD86, and CD1a was expressed by half of these cells. All of them highly expressed HLA class I and II molecules and CD40 (data not shown). For patient L1, differentiation into DCs produced a similar phenotype to that for healthy donors and the cells obtained did not express significant levels of CD14, CD16 or CD64. For patient L2, differences were observed: on one-third of the DCs, CD14 and CD64 remained expressed, and most of them were positive for CD16 and CD32.
The MØs obtained from lymphoma patients mostly expressed the characteristic markers CD14, CD40 and CD64. However, some differences with the MØs derived from normal volunteer monocytes were observed: the level of expression of CD80 and CD86 was lower. Moreover, 31% of L2 MØs expressed CD1a, and 25% of the MØs derived from L1 expressed CD1c, which are characteristic of DCs.
MØs and DCs show different APC function Induction of alloreactive T cell responses:
The initiation of a T lymphocyte immune response requires the expression of adhesion molecules which promote conjugate formation, recognition by the T cell receptor (TCR) of both antigen and major histocompatibility complex (MHC) determinants on the surface of APC and the expression of co-stimulatory ligands which deliver important activation signals independent of TCR occupancy. The level of expression of these molecules on MØs and DCs seems to condition the level of induction of the T cell response. Allogeneic one-way mixed lymphocyte reaction allowed comparison of the capacity of APCs to induce the proliferation of T cells independently of antigen. We used this assay to compare the APC function of uncultured APC (monocytes and B lymphocytes), MØs, and DCs from normal volunteers or lymphoma patients. Figure 2 shows that DCs had a greater ability to stimulate T cell proliferation than monocytes and MØs, the level of response being three-to 20-fold higher at 0.5/1 APC/T ratio. With DCs, the proliferative responses increased proportionally with the number of cells added in culture. The results also show that APC function of DCs from lymphoma patients was either slightly higher or slightly lower compared to that of DCs from normal donors.
Antigen presentation of soluble antigens:
Uptake and processing of soluble antigen has been reported to be efficient in immature DCs because of the high pinocytic capacity of these cells. 27 To study the efficiency of our cultured APC to take up, process, present exogenous antigen and prime naive T cells, we evaluated their ability to present the soluble KLH antigen.
Leukemia
Elutriated DCs and MØs and purified day 0 APC were incubated with increasing amounts of KLH in the presence of autologous T cells. As shown in Figure 3 (4 upper panels), DCs generated from both normal volunteers and lymphoma patients efficiently induced naive T cell proliferation. A dosedependent response was observed, beginning with 10 g/ml of KLH. Neither day 0 APC nor cultured MØs were able to prime T cells in response to KLH antigen. We then tested the ability of APC to present the recall antigen PPD (purified protein derivative). As shown in Figure 3 (2 lower panels) , MØs and day 0 APC from patient or donor were efficient in stimulating a memory T cell response. However, in the same conditions, DCs induced the highest proliferation of T cells.
MØs but not DCs are able to engulf tumor cells via Fc receptor
Phagocytosis is an efficient pathway for major histocompatibility complex class II and also class I presentation of exogenous antigen. 15, 16, 34 The macrophage capacity for phagocytosis is well known. 35 More recently, dendritic cells have also been reported to engulf particles like yeast or bacteria. 36, 37 We tested first the capacity of APC cultured in our system to phagocytose opsonized bacteria. Flow cytometry was used to quantify and compare the engulfment of fluorescent E. coli by monocytes, MØs and DCs. The results showed that both monocytes and MØs developed a high phagocytic capacity, with 47 to 76% of cells having engulfed bacteria (Figure 4) . However, the percentage of phagocytic MØs derived from normal volunteers (60%) was slightly higher compared to MØs derived from lymphoma patients (53%). In the same conditions, DCs showed a more moderate phagocytic rate since only 19 to 25% of cells were able to phagocytose the opsonized bacteria.
We then performed experiments to explore the capacity of APC to phagocytose whole tumor cells. Recently, some reports have shown that MØs 38 and DCs 39 are able to present antigens to CTL after engulfment of entire apoptotic cells. Moreover, the Fc receptor-mediated phagocytosis pathway seems to have an important role in the function of these APCs. 13 , 40 Here, we tested the capacity of APCs to phagocytose opsonized lymphoma cells. We used the chimeric anti-CD20 monoclonal antibody already tested for several years in clinical trials. 41 After a 1.5 h incubation, 37% of MØs generated from healthy volunteers and 23% of MØs from lymphoma patients were able to engulf opsonized malignant B cells (Table 2 and Figure 5 ). Conversely, no phagocytosis of malignant B cells by DCs generated from healthy donors was detected, and only 6% of the DCs differentiated from lymphoma patient L2 phagocytosed opsonized malignant B cells (Table 2) .
T cells cocultured with dendritic cells or macrophages are functional
In our culture system, we used the entire PBMC fraction. So, together with monocytes that will differentiate into DCs or MØs, T lymphocytes are present in the bag throughout the culture. We wondered what was the status of these cells in terms of activation and functionality. Indeed, it could be of great interest to use them as effector cells and prime them in the bag at the end of the culture.
We first analyzed T lymphocytes by flow cytometry at the
Figure 2
Allogeneic response induced by day 0 APC, DCs and Mлs. For healthy donors N5 and N6 and lymphoma patients L1 and L2 day 0 APC (B lymphocytes plus monocytes), day 6 DCs and day 7 Mлs were purified and used as stimulators for allogenic CD2 + lymphocytes purified by rosetting. The proliferative response was measured by 18 h 3 H thymidine uptake at the end of 6 day cultures.
beginning and the end of the culture. The results showed that the phenotype of T cells did not change significantly; the CD4/CD8 ratio was similar and they did not express activation markers like CD25 or HLA-DR after culture either with GM-CSF or GM-CSF/IL-13 (data not shown). The functionality of the T cells was first analyzed by their ability to proliferate when stimulated with mitogenic signals. The proliferation induced by phytohemaglutinin A, Concanavalin A, pokeweed mitogen or anti-CD3 mAb of T cells recovered after coculture with DCs or MØs was not modified compared with the day 0 uncultured T cells proliferation (Figure 6a and b) . In order to use the cultured DCs to initiate a primary response to a defined antigen, we also asked whether the T cells present in the bag could be primed and proliferate in response to KLH presented by the DCs with which they were cocultured. T cells from either normal volunteers or lymphoma patients could be efficiently primed (Figure 6c and d) .
Discussion
Over the past few years, new insights have arisen in the field of lymphoma immunology. Data collected form clinical trials and in vitro analysis have indicated that the immune system of patients could be solicited to eradicate tumor cells. Indeed, we and others have shown that antitumor lymphocytes could be expanded in vitro. 4, 5 Moreover, other groups have shown that T lymphocytes were able to be stimulated in vivo by the tumor idiotype and to generate cellular and clinical antitumor responses, in spite of previous aggressive therapy. 7, 42 The recent clinical trial in lymphoma using tumor-loaded DCs 8 highlights that professional APCs can be used for taking up, processing and presenting tumor protein in a vaccine strategy in cancer. MØs and DCs are the two populations of APC currently used in immune strategy. Each type of APC can develop different cellular activity depending on the differentiation and activation processes. In the context of the generation of an immune response, activation of naive T cells is suggested to be highly dependent on DCs, whereas memory T cells could be stimulated either by DCs or by MØs. However, recent work has shown that MØs are also able to stimulate naive T cells in some conditions. 25, 26, 43 At the moment, it is not clear which type of T cells, naive or memory lymphocytes, must be activated in vivo to generate an effective antitumor response and so which type of APC ought to be used. Other parameters should be taken into account for the choice of APC in cancer vaccine, such as the kind of cancer, the tumor location and the availability of tumor antigen(s).
The DC vaccine described by Hsu and colleagues 8 can be considered as a pioneer study in the immunotherapeutic field in lymphoma. However, this study presents several inconveniences for large-scale use. Indeed, the tumor antigen used is the tumor idiotype which is unique for each patient and so requires a specific and time-consuming purification procedure. Moreover, few DCs were recovered after purification from leukapheresis, and contained T cells and monocytes as contaminant cells in a significant proportion. In this context, we have described for the first time the generation of purified MØs and DCs from blood monocytes from lymphoma patients.
We used a standardized culture system allowing the generation of large number of clinical grade cells according to the MAK and VAC cell processor from Immuno-Designed Molecules. Cells were cultured in non-adherent bags with medium already used for therapeutic application. MØs were produced in the presence of GM-CSF, whereas DCs were Autologous T lymphocyte response to exogenous soluble antigen, KLH and PPD, in the presence of day 0 APC, DCs and Mлs. Autologous T lymphocytes were cocultured with APC purified from healthy donors N5 and N5 and lymphoma patients L1 and L2, in a T/APC ratio of 10/1, in the presence of various doses of KLH (4 upper panels) or 2500 U/ml of PPD (2 lower panels). The proliferative response of responding autologous T lymphocytes was measured by 18 h 3 H thymidine uptake at the end of day 6 cultures.
obtained after culture with GM-CSF and IL-13. We supplemented medium with autologous human serum in place of fetal calf serum, avoiding any xeno-contamination of cells. The cells were withdrawn from patients by apheresis, washed to eliminate platelets and put directly in culture without any prior purification. The number of DCs and MØs recovered at the end of culture depends directly on the number of monocytes. In this report, more than 100 million DCs and MØs were generated from 500 million mononuclear cells. The potential number of APC generated by the cell processors is considerable since 10 billion cells can be obtained from apheresis and cultured in bags. After 1 week, it would be possible to obtain 2 × 10 9 dendritic cells or macrophages in only one procedure since there is usually 20% monocytes in apheresis products. This system gave quite comparable results with mononuclear cells from either normal or lymphoma donors, suggesting that in spite of previous chemotherapy monocytes from patients have retained the potential to differentiate into MØs or DCs. Cells could be aliquoted and cryopreserved for multiple injections at different times for a therapeutic application.
This differentiation, evaluated by immunological analysis, showed that normal monocytes cultured for 1 week, in the presence of GM-CSF and IL-13 or of GM-CSF alone, acquired Leukemia the markers of DCs and MØs, respectively. MØs expressed CD14, CD64, HLA and costimulatory molecules, and receptors for complement proteins and immunoglobulins, but they did not express CD1 molecules. In contrast, CD1a and CD1c markers were expressed by DCs which were negative for CD14 and CD64 molecules. DCs expressed higher levels of HLA and costimulatory molecules than MØs, and also were positive for receptors for complement proteins but only for the medium-affinity IgG receptor (CD32). The expression of immunoglobulin receptors is of interest since they can modulate the function of DCs and play an important role in the uptake of antigens. 13 DCs produced using GM-CSF/IL-13 are considered as immature since they did not express CD83 molecules, but they have the potential to mature under the influence of TNF (data not shown). Differentiation of monocytes into DCs or MØs was comparable in patient L1 and normal donors but slightly different in patient L2. Indeed some cells from patient L2 cultured in the presence of GM-CSF and IL-13 expressed CD14 and some cells cultured in the presence of GM-CSF alone were positive for CD1a. However, these phenotypes did not interfere with the functionality of cells since they were quite comparable to APC generated from normal cells in terms of capacity to induce T cell responses.
As described, DCs were more efficient stimulators of naive,
Figure 4
Phagocytosis of opsonized bacteria by monocytes, DCs and Mлs. The ability of the different kinds of APC available to engulf opsonized FITC-labeled E. coli was analyzed by flow cytometry. Cells were incubated for 2 h at 37°C (filled histograms) or at 4°C (empty histograms). The percentage of phagocytic APC is indicated. These four experiments performed with cells from two healthy donors (N2 and N5) and two lymphoma patients (L1 and L2) are representative of six. memory and alloreactive T cells than MØs. The expression of higher levels of HLA and costimulatory molecules on DCs than on MØs could be responsible for this difference. The fact that MØs were not activated could also explain the weak level of stimulation of T cells. Indeed, the activation of MØs by ␥-IFN is described as crucial for their function in lymphocyte stimulation. 44 However, without stimulation, MØs have a great ability to uptake antigen via the phagocytosis pathway. Indeed, like monocytes, a large fraction of macrophages efficiently engulfed bacteria. The slightly lower phagocytic activity observed for MØs derived from lymphoma patients compared to normal volunteers could be related to the lower expression of CD16 (37% for patient L2) or CD32 (35% for patient L1) on MØs. In contrast, DCs showed moderate phagocytosis. The fact that monocytes and MØs express all receptors for immunoglobulins probably explains their greater ability to engulf opsonized bacteria than DCs, even though other molecules like complement and lectin receptors are also involved in phagocytosis of such particles. However, DCs produced in the same conditions have been described to have a strong ability to phagocytose yeasts via mannose receptor. 32 In lymphoma, apart from tumor immunoglobulin, no tumor antigen is for the moment available. This is why it would be interesting to use whole tumor cells as a source of antigen. Thus, all tumor antigens are potentially available, whether they are unique or shared with other lymphomas. In other cancers, tumor RNA 45 or lysates 9,10,46,47 from whole cells have already been used for pulsing DCs before injecting them in mice and man. Moreover, MØs and DCs have been described as taking up antigen by engulfing apoptotic cells. 38, 39 The chimeric anti-CD20 monoclonal antibody has been used with therapeutic success. 41 Therefore, we performed experiments using opsonized whole tumor cells to pulse APCs with tumor antigen. In a short incubation (90 min), we observed that MØs from normal or lymphoma donors were able to phagocytose tumor cells only when CD20 was added. In contrast, minimal or no phagocytic activity was detected with dendritic cells. These results could be related to immunoglobulin receptors a b
Figure 5
Phagocytosis of CD20-opsonized malignant B cells by Mлs. The ability of purified macrophages from healthy donor N6 (a) and lymphoma patients L2 (b) to phagocyte non-opsonized malignant B cells (left photos) or opsonized (middle and right photos). Malignant B cells and MØs were mixed together, and incubated for 90 min at 37°C. Cytospins of cell suspensions were made and slides were stained with May-Grunwald Giemsa. Original magnification ×40.
which are better expressed on macrophages than on dendritic cells. The demonstration that MØs could engulf CD20 opsonized-lymphoma cells is of interest for the development of new therapeutic strategies. Indeed, injections of MØs with CD20 could be considered to both eradicate tumor cells and then induced antitumor responses by presenting tumor proteins efficiently to T lymphocytes. In a murine model, recent data have suggested that such a mechanism could be implicated in the eradication of an established solid tumor. 48 DCs do not seem able to phagocytose tumor cells opsonized with monoclonal antibody, therefore, additional manipulation of tumor cells is required to allow the uptake of tumor antigen by DCs from whole tumor cells in lymphoma. In this way, DCs could be activated by INF-␥ to up-regulate Fc receptors as previously described, 49 to perform CD64-and CD32-mediated phagocytosis.
Finally, we show in this report that T lymphocytes cocultured with monocytes during the differentiation into macrophages or dendritic cells are comparably functional to uncultured T cells. This means that it is possible to use these cells in vitro to begin the induction of antitumor responses with MØs or DCs pulsed with tumor antigens. This could be the first step of a therapeutic protocol.
The results presented here show that large numbers of APC (macrophages or dendritic cells) can be generated from peripheral blood mononuclear cells from patients with lymphoma in spite of their disease and previous therapy. These cells were produced using a simple procedure in conditions compatible with therapeutic application. The potential use of macrophages or dendritic cells may depend on the nature of tumor antigens and also on the type of T cell response that is required (naive or memory). The combination of MØs and CD20 could represent the basis for the development of new clinical trials.
